Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 23 April 2021, including: possible new life for Tecfidera; activist investors and GSK; a new mRNA vaccine in Europe; diversity in clinical trials; and a look at last year’s drug launches amid the pandemic.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen" - Scrip, 19 Apr, 2021.)

(Also see "Twitchy Times At GSK As Activist Investor Takes Big Stake" - Scrip, 16 Apr, 2021.)

(Also see "CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach" - Scrip, 16 Apr, 2021.)

(Also see "#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity" - Scrip, 16 Apr, 2021.)

(Also see "Worldwide Novel Drug Launches Soared Amid Pandemic" - Scrip, 19 Apr, 2021.)

 

Related Content

Topics

UsernamePublicRestriction

Register

SC144243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel